Searchable abstracts of presentations at key conferences in endocrinology

ea0015p370 | Thyroid | SFEBES2008

A trial of radioiodine with and without adjuvant lithium therapy in the treatment of hyperthyroidism

Mitchinson S , Nijher GMK , Meeran K , Martin N

Background: Radioiodine (RAI) is highly effective in the treatment of hyperthyroidism. Lithium reduces thyroidal release of organic iodide and thyroid hormones, thus increasing thyroid retention of RAI and subsequently, the delivered dose of radiation. Controversy surrounds whether lithium increases the efficacy of RAI.Aims: To assess whether lithium improved outcome after radioiodine treatment and analyse fT4 and eye disease changes in lithium treatment...

ea0015p371 | Thyroid | SFEBES2008

Use of a telephone clinic to follow up patients post-radioiodine treatment

Mitchinson S , Nijher GMK , Meeran K , Martin N

Background: Close follow up of patients treated with radioiodine (RAI) for hyperthyroidism is imperative to ensure that resultant hypothyroidism or ensuing hyperthyroidism is detected promptly and treated. Protocols of follow up vary between hospitals. In our centre, a telephone clinic is used and patients are called after thyroid function tests at 1, 3, 6, 9 and 12 weeks post radioiodine.Aims: To audit patient follow up in the telephone clinic, comparin...

ea0012p87 | Pituitary | SFE2006

ACTH hyperplasia and prolactinoma in MEN 1

Caputo C , Martin N , Roncaroli F , Todd J , Meeran K

A 37-year old gentleman with MEN 1 was referred to our Centre for further assessment. MEN 1 had manifested as recurrent primary hyperparathyroidism and multiple pancreatic gastrinomas. He complained of reduced libido, with absent early morning erections for the preceding 18 months. Biochemistry confirmed hyperprolactinaemia (prolactin 1494, NR 0–625 mU/l, testosterone 12 NR 10–28 nmol/l, LH 2.6 NR 2–12 IU/l, FSH 3.7 NR 1.7–8 IU/l). During investigation of h...

ea0010p30 | Diabetes, metabolism and cardiovascular | SFE2005

How empowered are patients with type II diabetes?

Martin N , Jayasena C , Morganstein D , Devendra D , Dornhorst A

The National Service Framework (NSF) for Diabetes requires that type II diabetes patients are actively involved in their diabetes management. The use of patient-held, integrated care plans is envisaged to encourage patients to actively participate in their diabetes management and to facilitate the flow of information between primary and secondary care. However, the utility of such schemes may be limited by the current level of patient education regarding the data recorded in t...

ea0010dp9 | Diabetes, metabolism and cardiovascular | SFE2005

How empowered are patients with type II diabetes?

Martin N , Jayasena C , Morganstein D , Devendra a D , Dornhorst A

The National Service Framework (NSF) for Diabetes requires that type II diabetes patients are actively involved in their diabetes management. The use of patient-held, integrated care plans is envisaged to encourage patients to actively participate in their diabetes management and to facilitate the flow of information between primary and secondary care. However, the utility of such schemes may be limited by the current level of patient education regarding the data recorded in t...

ea0003p156 | Genetics | BES2002

Seven novel mutations in the androgen receptor gene associated with complete androgen insensitivity syndrome

Jaaskelainen J , Mongan N , Martin H , Hughes I

Complete androgen insensitivity syndrome (CAIS), is generally caused by a mutation in the androgen receptor (AR) gene. In sequencing genomic DNA from patients with CAIS, we identified 7 novel mutations in the AR. Their effects on AR function are speculated in relation to AR functional domains and crystal structure. Local Ethical Committee approval was obtained for the use of patient samples.Exon 1 mutations, Q86X and Y480X, are located in the transactiv...

ea0029p1260 | Obesity | ICEECE2012

Usefulness of preoperativee exenatide in control of risk factors for bariatric surgery on type 2 diabetic patients with morbid obesity

Martin-Hernandez T. , Clara G. , Gonzalez N. , Martin V. , Torres A. , Gentil A. , Morales A.

Introduction: The aim of this study was to evaluate effects on glycemic control, body weight and cardiovascular risk factors (BP, lipids and Epworth sleepiness scale) in diabetic patients with morbid obesity treated with exenatide.Material and methods: We studied consecutively 21 T2DM patients, all of them treated with metformin full dosage and insufficient metabolic control referred to our clinic for preoperative control of bariatric surgery. Twelve of ...

ea0013s46 | Management of endocrine disorders in pregnancy: the mother and the child | SFEBES2007

CAH – pregnancy and antenatal glucocorticoid treatment

Lajic Svetlana , Nordenström Anna , Hirvikoski Tatja , Wedell Anna , Ritzén Martin

In foetuses at risk of virilising CAH, prenatal treatment can be offered by administration of dexamethasone (DEX) via the mother in order to prevent genital malformations. Accumulating evidence from animal studies and epidemiological data raise concerns regarding the long term consequences of excess glucocorticoids on the developing foetus. The European study PREDEX is organized as an open, controlled, non-randomised, multicentre trial. The impact of DEX on the general well-be...

ea0012p83 | Pituitary | SFE2006

Pituitary macroadenomas: are combination antiplatelet and anticoagulant therapy contraindicated?

Tan TM-M , Caputo C , Mehta A , Hatfield E , Martin N , Meeran K

We describe a case of pituitary apoplexy in a patient with a known non- functioning macroadenoma. A 57 year old female was incidentally found to have a 20 x 16 mm solid and cystic pituitary mass abutting the optic chiasm on MRI scanning. She had gonadotrophin deficiency on endocrine testing and normal visual fields. Although repeat perimetry 12 months later revealed a mild superior bi-temporal hemianopia, the patient elected not to have surgery.Several m...

ea0010p57 | Pituitary | SFE2005

The low dose dexamethasone suppression test with CRH is not reliable following pituitary surgery

Abdulali A , Banerjee A , Martin N , Dhillo W , Todd J , Mendoza N , Meeran K

The definition of early cure post transphenoidal surgery (TSS) for Cushing’s disease continues to be debated. The low dose dexamethasone suppression test with corticotrophin releasing hormone (LDDST-CRH) is a test for diagnosis of Cushing’s; however it has not been validated in early post TSS to determine remission. The aim of this study was to determine whether the combined LDDST-CRH test could be used in post TSS patients.The combined LDDST-C...